Clot Risk of Lilly’s Lung Cancer Drug Raises Concerns at FDA

Eli Lilly & Co.’s experimental lung cancer drug raised concerns with U.S. regulators that it may increase patients’ risk of suffering potentially deadly blood clots.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.